$-0.12 EPS Expected for Novavax, Inc. (NVAX)

October 11, 2018 - By Louis Casey

Novavax, Inc. (NASDAQ:NVAX) LogoInvestors sentiment increased to 2.11 in Q2 2018. Its up 0.55, from 1.56 in 2018Q1. It improved, as 16 investors sold Novavax, Inc. shares while 21 reduced holdings. 25 funds opened positions while 53 raised stakes. 160.47 million shares or 7.74% more from 148.94 million shares in 2018Q1 were reported.
Piedmont Advisors Ltd Limited Liability Company reported 6,619 shares. Wells Fargo & Mn, California-based fund reported 537,765 shares. Two Sigma Lc stated it has 0% in Novavax, Inc. (NASDAQ:NVAX). Quantitative Invest Mngmt Limited reported 230,300 shares stake. The Maryland-based Profund Advsrs Limited Liability Corporation has invested 0% in Novavax, Inc. (NASDAQ:NVAX). Tower Rech Limited Liability Corp (Trc) has invested 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). Bancorp Of America De invested 0% in Novavax, Inc. (NASDAQ:NVAX). Jacobs Levy Equity holds 0.02% or 881,709 shares. Valley National Advisers Inc reported 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX). 8.33 million are owned by Bb Biotech Ag. Renaissance Tech Lc invested in 0.01% or 5.79M shares. Waters Parkerson And Ltd Liability Corp owns 0% invested in Novavax, Inc. (NASDAQ:NVAX) for 10,000 shares. California State Teachers Retirement Systems, California-based fund reported 583,412 shares. 44,900 were reported by Crestwood Advsr Gru Limited Liability. Sei invested 0% in Novavax, Inc. (NASDAQ:NVAX).

Since May 14, 2018, it had 3 insider purchases, and 0 sales for $208,866 activity. 20,000 shares valued at $32,800 were bought by Glenn Gregory M on Monday, May 14.

Analysts expect Novavax, Inc. (NASDAQ:NVAX) to report $-0.12 EPS on November, 6.They anticipate $0.03 EPS change or 20.00 % from last quarter’s $-0.15 EPS. After having $-0.12 EPS previously, Novavax, Inc.’s analysts see 0.00 % EPS growth. The stock decreased 6.34% or $0.13 during the last trading session, reaching $1.92. About 8.22 million shares traded or 53.61% up from the average. Novavax, Inc. (NASDAQ:NVAX) has risen 28.07% since October 11, 2017 and is uptrending. It has outperformed by 12.45% the S&P500.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

Among 2 analysts covering Novavax (NASDAQ:NVAX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novavax had 2 analyst reports since May 17, 2018 according to SRatingsIntel. FBR Capital maintained the stock with “Buy” rating in Thursday, May 17 report. The company was upgraded on Friday, September 21 by JP Morgan.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $734.58 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

More notable recent Novavax, Inc. (NASDAQ:NVAX) news were published by: Seekingalpha.com which released: “Novavax Shares Strengthen As A Key Catalyst Approaches” on September 25, 2018, also Benzinga.com with their article: “ResVax, NanoFlu Prospects Earn Novavax A Double Upgrade” published on September 21, 2018, Globenewswire.com published: “Novavax to Present at Two Upcoming Investor Conferences” on September 26, 2018. More interesting news about Novavax, Inc. (NASDAQ:NVAX) were released by: Fool.com and their article: “Here’s Why Novavax Gained 20.5% in September” published on October 10, 2018 as well as Seekingalpha.com‘s news article titled: “Novavax, Inc. (NVAX) Presents at Ladenburg Thalmann 2018 Healthcare Conference (Transcript)” with publication date: October 02, 2018.

Novavax, Inc. (NASDAQ:NVAX) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.


Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Market News